SEOUL, July 18 (Yonhap) — Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, said Friday it has signed a partnership with a U.S. company to sell its ophthalmology biosimilars in the United States.
The company signed a commercialization agreement with Harrow Inc., a leading U.S. eye care pharmaceutical company, to sell Byooviz and Opuviz through Harrow’s sales network, it said in a press release.
Byooviz and Opuviz are biosimilars of the original drugs Lucentis and Eylea, respectively.
The agreement will take effect upon completion of the transfer of commercial rights from U.S. biotechnology firm Biogen Inc. to Samsung Bioepis by the end of 2025, the company said.
Samsung Bioepis said it plans to work closely with Harrow, which has strong capabilities in commercializing ophthalmic pharmaceutical products in the North American market.
This file photo, provided by Samsung Bioepis Co., shows its headquarters in Songdo, just west of Seoul. (PHOTO NOT FOR SALE) (Yonhap)
kyongae.choi@yna.co.kr